# Examining Sex Differences in Weight Loss Efficacy of Retatrutide and Other GLP-1RAs

Canonical source: https://retacompare.com/research/examining-sex-differences-in-weight-loss-efficacy-of-retatrutide-and-other-glp-1ras

Weight Loss Outcomes · 2025-03-01


    Recent research indicates that females experience greater weight loss than males when treated with GLP-1 receptor agonists (GLP-1RAs) like Retatrutide. This finding is particularly relevant for clinicians and researchers focusing on the efficacy of these medications for weight management. The systematic review and meta-analysis included multiple GLP-1RAs and highlighted significant sex differences in weight reduction outcomes.

 What this source covers

This study systematically reviews randomized controlled trials (RCTs) that report weight change by sex among patients treated with GLP-1 receptor agonists, including Retatrutide. The meta-analysis incorporated 14 studies that evaluated various GLP-1RAs, such as dulaglutide, exenatide, liraglutide, semaglutide, and Retatrutide. The findings indicate that females lost more weight than males, with a mean difference of 1.04 kg. Additionally, the research explored the impact of treatment indications on the observed sex differences in weight reduction.

 Why it matters for Retatrutide research

The findings of this meta-analysis are particularly significant for ongoing research into Retatrutide, as they suggest that sex-specific responses to GLP-1RAs may influence treatment outcomes. Understanding these differences can help tailor weight management strategies and improve patient care. As Retatrutide continues to be studied, recognizing the potential for greater efficacy in females may lead to more personalized approaches in clinical practice.

 Key findings or claims

Females lost more weight than males when treated with GLP-1RAs, with a mean difference of 1.04 kg.

The pooled results for all GLP-1RAs indicated a mean weight reduction of 0.88 kg.

Subgroup analysis revealed that treatment indications for weight reduction magnified the gender difference, with a mean difference of 4.21 kg.

Dulaglutide and semaglutide showed statistically significant differences in weight reduction between sexes.

No gender differences were observed in the exenatide subgroup analysis.

Meta-regression analysis indicated that greater weight reduction was significantly associated with increased gender differences.

 Context and prior work

This study builds upon existing literature regarding the efficacy of GLP-1 receptor agonists, which have been shown to be effective for weight management in various populations. Prior research has indicated that hormonal and metabolic differences between sexes may influence the pharmacodynamics of weight loss medications. As Retatrutide is part of this class of drugs, understanding these nuances is essential for maximizing its therapeutic potential. The overall body of research on GLP-1RAs suggests that sex differences are an important consideration in clinical trials and practice.

 Practical takeaways for researchers

Researchers and clinicians should consider sex differences when evaluating the efficacy of Retatrutide and other GLP-1RAs in weight management. The evidence suggests that females may respond more favorably to these treatments, which could inform patient selection and treatment protocols. Future studies should continue to explore these differences and their implications for clinical practice, potentially leading to more effective weight management strategies.

 FAQ

 What are GLP-1 receptor agonists?

GLP-1 receptor agonists are a class of medications that mimic the action of the glucagon-like peptide-1 hormone, which helps regulate appetite and glucose metabolism.

 How does Retatrutide compare to other GLP-1RAs?

Retatrutide is one of several GLP-1 receptor agonists that have been studied for weight reduction, and it is important to consider sex differences in efficacy when comparing it to others.

 Why are sex differences important in weight loss research?

Understanding sex differences is crucial for developing personalized treatment approaches, as they can significantly influence the efficacy of weight loss medications.

 Source: PubMed · J Diabetes · published 2025-03-01.

## Sources

- PubMed · J Diabetes: https://pubmed.ncbi.nlm.nih.gov/40040445